EUVIMEDEUVIMED entdecken
Crossref

Tumor-Naïve Circulating Tumor DNA as an Early Response Biomarker for Patients Treated With Immunotherapy in Early Phase Clinical Trials

Enrique Sanz-Garcia iD, Sofia Genta, Xiaoxi Chen, Qiuxiang Ou iD, Daniel V Araujo iD, Albiruni R Abdul Razak iD, Aaron R Hansen iD, Anna Spreafico, Hua Bao iD, Xue Wu, Lillian L Siu, Philippe L Bedard iD

JCO Precision Oncology · 2023-04 · (7)

DOI: 10.1200/po.22.00509 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2023-04. Verfasst von Enrique Sanz-Garcia und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University Health Network, University of Toront…. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Cell-Free Nucleic Acids, Lung Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To evaluate early circulating tumor DNA (ctDNA) kinetics using a tumor-naïve assay and correlate it with clinical outcomes in early phase immunotherapy (IO) trials. METHODS Plasma samples were analyzed using a 425-gene next-generation sequencing panel at baseline and before cycle 2 (3-4 weeks) in patients with advanced solid tumors treated with investigational IO agents. Variant allele frequency (VAF) for mutations in each gene, mean VAF (mVAF) from all mutations, and change in mVAF between both time points were calculated. Hyperprogression (HyperPD) was measured using Matos and Caramella criteria. RESULTS A total of 162 plasma samples were collected from 81 patients with 27 different tumor types. Patients were treated in 37 different IO phase I/II trials, 72% of which involved a PD-1/PD-L1 inhibitor. ctDNA was detected in 122 plasma samples (75.3%). A decrease in mVAF from baseline to precycle 2 was observed in 24 patients (37.5%) and was associated with longer progression-free survival (hazard ratio [HR], 0.43; 95% CI, 0.24 to 0.77; P < .01) and overall survival (HR, 0.54; 95% CI, 0.3 to 0.96; P = .03) compared with an increase. These differences were more marked if there was a >50% decrease in mVAF for both progression-free survival (HR, 0.29; 95% CI, 0.13 to 0.62; P < .001) and overall survival (HR, 0.23; 95% CI, 0.09 to 0.6; P = .001). No differences in mVAF changes were observed between the HyperPD and progressive disease patients. CONCLUSION A decrease in ctDNA within 4 weeks of treatment was associated with treatment outcomes in patients in early phase IO trials. Tumor-naïve ctDNA assays may be useful for identifying early treatment benefits in phase I/II IO trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNACell-Free Nucleic AcidsLung NeoplasmsHumansBiomarkers, TumorDNA, NeoplasmDisease ProgressionImmunotherapy

Substanzen

Circulating Tumor DNACell-Free Nucleic AcidsBiomarkers, TumorDNA, Neoplasm

Autor:innen und Institutionen

  • Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada.
  • Geneseeq Technology Inc, Toronto, Canada.
  • Division of Medical Oncology, Hospital de Base, Sao Paulo, Brazil.

ORCID-Profile: Enrique Sanz-Garcia, Qiuxiang Ou, Daniel V Araujo, Albiruni R Abdul Razak, Aaron R Hansen, Hua Bao, Philippe L Bedard

Zitieren

APA

Sanz-Garcia, E., Genta, S., Chen, X., Ou, Q., Araujo, D. V., Abdul Razak, A. R., Hansen, A. R., Spreafico, A., Bao, H., Wu, X., Siu, L. L., & Bedard, P. L. (2023). Tumor-Naïve Circulating Tumor DNA as an Early Response Biomarker for Patients Treated With Immunotherapy in Early Phase Clinical Trials. JCO Precision Oncology. https://doi.org/10.1200/po.22.00509

Vancouver

Sanz-Garcia E, Genta S, Chen X, Ou Q, Araujo DV, Abdul Razak AR, et al. Tumor-Naïve Circulating Tumor DNA as an Early Response Biomarker for Patients Treated With Immunotherapy in Early Phase Clinical Trials. JCO Precision Oncology. 2023. doi:10.1200/po.22.00509

BibTeX
@article{SanzGarcia2023,
  author = {Sanz-Garcia, Enrique and Genta, Sofia and Chen, Xiaoxi and Ou, Qiuxiang and Araujo, Daniel V and Abdul Razak, Albiruni R and Hansen, Aaron R and Spreafico, Anna and Bao, Hua and Wu, Xue and Siu, Lillian L and Bedard, Philippe L},
  title = {Tumor-Naïve Circulating Tumor DNA as an Early Response Biomarker for Patients Treated With Immunotherapy in Early Phase Clinical Trials},
  journal = {JCO Precision Oncology},
  year = {2023},
  number = {7},
  doi = {10.1200/po.22.00509}
}
Kostenlos starten →